A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Part 2 Expansion will enroll only pancreatic cancer, colorectal cancer and cholangiocarcinoma

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 20-2976

More information available at ClinicalTrials.gov: NCT04666688

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers